- Home
- BEATW vs WLDN Comparison
BEATW vs WLDN Comparison
Compare BEATW & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- WLDN
- Stock Information
- Founded
- BEATW 2015
- WLDN 1964
- Country
- BEATW United States
- WLDN United States
- Employees
- BEATW N/A
- WLDN N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- WLDN Military/Government/Technical
- Sector
- BEATW Technology
- WLDN Consumer Discretionary
- Exchange
- BEATW Nasdaq
- WLDN Nasdaq
- Market Cap
- BEATW N/A
- WLDN N/A
- IPO Year
- BEATW N/A
- WLDN 2006
- Fundamental
- Price
- BEATW $0.57
- WLDN $32.21
- Analyst Decision
- BEATW
- WLDN Strong Buy
- Analyst Count
- BEATW 0
- WLDN 3
- Target Price
- BEATW N/A
- WLDN $44.33
- AVG Volume (30 Days)
- BEATW 4.7K
- WLDN 122.5K
- Earning Date
- BEATW 03-14-2025
- WLDN 03-06-2025
- Dividend Yield
- BEATW N/A
- WLDN N/A
- EPS Growth
- BEATW N/A
- WLDN 802.09
- EPS
- BEATW N/A
- WLDN 1.63
- Revenue
- BEATW N/A
- WLDN $577,414,000.00
- Revenue This Year
- BEATW N/A
- WLDN N/A
- Revenue Next Year
- BEATW N/A
- WLDN $7.28
- P/E Ratio
- BEATW N/A
- WLDN $19.76
- Revenue Growth
- BEATW N/A
- WLDN 23.47
- 52 Week Low
- BEATW $0.50
- WLDN $19.70
- 52 Week High
- BEATW $0.62
- WLDN $50.00
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- WLDN 27.36
- Support Level
- BEATW N/A
- WLDN $33.96
- Resistance Level
- BEATW N/A
- WLDN $35.00
- Average True Range (ATR)
- BEATW 0.00
- WLDN 1.05
- MACD
- BEATW 0.00
- WLDN -0.18
- Stochastic Oscillator
- BEATW 0.00
- WLDN 9.55
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.